{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:05Z","timestamp":1789239965512,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective chart review of (<jats:italic>n<\/jats:italic>\u2009=\u200923) inpatients with opioid use disorder or opioid dependence due to chronic pain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety\u2010six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post\u2010discharge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>This strategy may facilitate buprenorphine therapy in hospital inpatients. (Am J Addict 2019;00:1\u20134)<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.12964","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T14:11:23Z","timestamp":1571407883000},"page":"73-76","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-9683","authenticated-orcid":false,"given":"Victor M.","family":"Tang","sequence":"first","affiliation":[{"name":"Mental Health and Addictions Service St. Michael's Hospital  Toronto Ontario Canada"},{"name":"Temerty Centre for Therapeutic Brain Intervention Centre for Addiction and Mental Health  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lam\u2010Shang\u2010Leen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinical Pharmacology and Toxicology University of Toronto  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Brothers","sequence":"additional","affiliation":[{"name":"Department of Medicine Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Hansen","sequence":"additional","affiliation":[{"name":"Mental Health and Addictions Service St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Caudarella","sequence":"additional","affiliation":[{"name":"Mental Health and Addictions Service St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiplove","family":"Lamba","sequence":"additional","affiliation":[{"name":"Mental Health and Addictions Service St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Guimond","sequence":"additional","affiliation":[{"name":"Mental Health and Addictions Service St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"e_1_2_6_1_2_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302885"},{"key":"e_1_2_6_1_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4077-z"},{"key":"e_1_2_6_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1311-3"},{"key":"e_1_2_6_1_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.2556"},{"key":"e_1_2_6_1_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy924"},{"key":"e_1_2_6_1_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2014.921743"},{"key":"e_1_2_6_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0228.x"},{"key":"e_1_2_6_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0866-8"},{"key":"e_1_2_6_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.04.001"},{"key":"e_1_2_6_1_11_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v25n04_09"},{"key":"e_1_2_6_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12869"},{"key":"e_1_2_6_1_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"e_1_2_6_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2011.00159.x"},{"key":"e_1_2_6_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31828bfb6e"},{"key":"e_1_2_6_1_16_1","unstructured":"Centre MGDNP. Canadian guideline for safe and effective use of opioids for chronic non\u2010cancer pain: appendix b\u20108.1 oral opioid analgesic conversion table.http:\/\/nationalpaincentre.mcmaster.ca\/opioid\/cgop_b_app_b08.html. Accessed October 5 2017."},{"key":"e_1_2_6_1_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2007.0285"},{"key":"e_1_2_6_1_18_1","unstructured":"Entity DoVHAMC. Vermont Buprenorphine Clinical Guidelines.http:\/\/dvha.vermont.gov\/for\u2010providers\/buprenorphine\u2010practice\u2010guidelines\u2010revised\u2010final\u201010\u201015.pdf.2015."},{"key":"e_1_2_6_1_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3949"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.12964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajad.12964","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.12964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T16:04:08Z","timestamp":1694189048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.12964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/ajad.12964"],"URL":"https:\/\/doi.org\/10.1111\/ajad.12964","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"2019-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}